Loading...
XHKG
2216
Market cap199mUSD
Jul 31, Last price  
2.97HKD
1D
-5.41%
1Q
29.13%
IPO
-79.80%
Name

Broncus Holding Corp

Chart & Performance

D1W1MN
XHKG:2216 chart
No data to show
P/E
P/S
24.57
EPS
Div Yield, %
Shrs. gr., 5y
-1.44%
Rev. gr., 5y
0.15%
Revenues
8m
-20.71%
8,072,0003,259,00010,891,0009,413,00010,255,0008,131,000
Net income
-15m
L-45.52%
-32,551,000-48,786,000-236,178,000-28,036,000-28,091,000-15,303,000
CFO
0k
P
-15,815,000-15,588,000-31,494,000-30,954,000-26,132,0000

Profile

Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. The company provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPro, a virtual bronchoscopic navigation product that provides three-dimensional real-time guided transbronchial needle aspiration and proprietary parenchymal navigation. It also offers treatment products comprising InterVapor, a targeted bronchoscopic thermal vapor ablation to ablate the diseased hyper-inflated lung segments; RF Generator + RF Ablation Catheter, a radiofrequency ablation system used in conjunction with a disposable lung radiofrequency ablation catheter, as well as radiofrequency ablation system that targets lung cancer; and H-Marker, a pulmonary surgical marker. In addition, the company provides treatment products, such as BioStarNeedle, a single use ultrasound-guided aspiration needle for retrieval of tissue samples; FleXNeedle, a multipurpose biopsy needle; Archimedes Sheath, a sterile single-use flexible tube that provides a working channel during a bronchoscopic procedure; Archimedes Dilation Balloon, a sterile single-use flexible tube with a balloon at or near the distal tip that is inserted through the bronchoscope or sheath and used to dilate the target lung tissue of the bronchial tree; and Steerable Sheath, a steerable sheath adjustment handle and a working channel. Broncus Holding Corporation was incorporated in 2012 and is headquartered in Hangzhou, China.
IPO date
Sep 24, 2021
Employees
314
Domiciled in
CN
Incorporated in
KY

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
8,131
-20.71%
10,255
8.95%
9,413
-13.57%
Cost of revenue
29,218
43,597
41,683
Unusual Expense (Income)
NOPBT
(21,087)
(33,342)
(32,270)
NOPBT Margin
Operating Taxes
3
3
3
Tax Rate
NOPAT
(21,090)
(33,345)
(32,273)
Net income
(15,303)
-45.52%
(28,091)
0.20%
(28,036)
-88.13%
Dividends
Dividend yield
Proceeds from repurchase of equity
55
119
BB yield
-0.01%
-0.01%
Debt
Debt current
318
1,131
681
Long-term debt
296
3,563
2,232
Deferred revenue
53
102
Other long-term liabilities
175
Net debt
(112,873)
(88,223)
(111,446)
Cash flow
Cash from operating activities
(26,132)
(30,954)
CAPEX
(664)
(856)
Cash from investing activities
5,486
(87,569)
Cash from financing activities
(1,459)
(572)
FCF
(56,990)
(33,930)
(37,926)
Balance
Cash
98,817
156,884
187,909
Long term investments
14,670
(63,967)
(73,550)
Excess cash
113,080
92,404
113,888
Stockholders' equity
169,477
(461,887)
(379,976)
Invested Capital
56,715
649,665
594,861
ROIC
ROCE
EV
Common stock shares outstanding
488,861
488,571
487,749
Price
0.59
-25.32%
0.79
-65.50%
2.29
-71.59%
Market cap
288,428
-25.27%
385,971
-65.44%
1,116,946
-53.65%
EV
175,554
297,747
1,005,500
EBITDA
(21,087)
(30,476)
(29,422)
EV/EBITDA
Interest
163
98
Interest/NOPBT